Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Genomic alterations in cancer can increase reliance on proteostasis.
• Proteasome inhibitors are clinically used for multiple myeloma and mantle cell lymphoma.
• Limited efficacy of proteasome inhibitors in other cancers necessitates exploring alternative targets.

Purpose of the Study:

• To investigate the limited applicability of proteasome inhibitors in cancer therapy.
• To explore alternative targets within the ubiquitin-proteasome system for broader cancer treatment.

Main Methods:

• Review of existing literature on proteostasis mechanisms in cancer.
• Analysis of the role of the ubiquitin-proteasome system (UPS) in cancer cell survival.
• Consideration of novel therapeutic targets within the UPS.

Main Results:

• Cancer cells' dependence on proteostasis is a key vulnerability.
• Proteasome inhibitors demonstrate specific efficacy, not universal applicability.
• Other UPS components may represent more generalizable therapeutic targets.

Conclusions:

• Targeting the ubiquitin-proteasome system remains a promising strategy for cancer therapy.
• Inhibiting ubiquitin-activating enzyme or p97/VCP could offer broader therapeutic potential than current proteasome inhibitors.
• Further research into novel UPS inhibitors is warranted for diverse cancer types.